

ENT COOPERATION TRE/

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

DONAHUE ERNST & YOUNG
Ernst & Young Tower
Suite 1800
222 Bay Street
P.O. Box 197, T.D. Centre
Toronto, Ontario M5K 1H6
CANADA

Date of mailing (day/month/year) 17 November 2000 (17.11.00)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 2282/2603	
International application No. PCT/CA99/00700	International filing date (day/month/year) 03 August 1999 (03.08.99)

1. The following indications appeared on record concerning:

☐ the applicant ☐ the inventor ☒ the agent ☐ the common representative

Name and Address DEETH WILLIAMS WALL National Bank Building Suite 400 150 York Street Toronto, Ontario M5H 3S5 Canada	State of Nationality	State of Residence
	Telephone No. 416 941 9440	
	Facsimile No. 416 941 9443	
	Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person ☒ the name ☒ the address ☐ the nationality ☐ the residence

Name and Address DONAHUE ERNST & YOUNG Ernst & Young Tower Suite 1800 222 Bay Street P.O. Box 197, T.D. Centre Toronto, Ontario M5K 1H6 Canada	State of Nationality	State of Residence
	Telephone No. 416 943 2400	
	Facsimile No. 416 943 2795	
	Teleprinter No.	

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer A. Karkachi Telephone No.: (41-22) 338.83.38
---	---

TENT COOPERATION TRE.

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
 United States Patent and Trademark
 Office
 Box PCT
 Washington, D.C.20231
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 28 September 2000 (28.09.00)	
International application No. PCT/CA99/00700	Applicant's or agent's file reference 2282/2603
International filing date (day/month/year) 03 August 1999 (03.08.99)	Priority date (day/month/year) 17 February 1999 (17.02.99)
Applicant POLLAK, Alfred et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

07 September 2000 (07.09.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer A. Karkachi</p> <p>Telephone No.: (41-22) 338.83.38</p>
--	--

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

RECEIVED

JUL 10 2001

PCT

To:

Donahue Ernst & Young LLP
Ernst & Young Tower
Toronto-Dominion Centre
222 Bay Street, Suite 1800
P.O. Box 197
Toronto, Ontario M5K 1H6
CANADA

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing
(day/month/year)

04.07.2001

Applicant's or agent's file reference
2274/003193

IMPORTANT NOTIFICATION

International application No.
PCT/CA99/00700

International filing date (day/month/year)
03/08/1999

Priority date (day/month/year)
17/02/1999

Applicant

RESOLUTION PHARMACEUTICALS INC. et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Almalé Murillo, J-A

Tel. +49 89 2399-8059



PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 2274/003193	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/CA99/00700	International filing date (day/month/year) 03/08/1999	Priority date (day/month/year) 17/02/1999
International Patent Classification (IPC) or national classification and IPC A61K51/08		
Applicant RESOLUTION PHARMACEUTICALS INC. et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 8 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 6 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 07/09/2000	Date of completion of this report 04.07.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Skjöldebrand, C Telephone No. +49 89 2399 8467



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/CA99/00700

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-24 as originally filed

Claims, No.:

1-44 with telefax of 23/05/2001

Drawings, sheets:

1/5-5/5 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/CA99/00700

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 26-34 with respect to I.A..

because:

- ☒ the said international application, or the said claims Nos. 26-34 with respect to I.A. relate to the following subject matter which does not require an international preliminary examination (*specify*):
see separate sheet
- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
- ☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims 1-44

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/CA99/00700

	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-44
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-25, 35-44 (26-34 see separate sheet)
	No:	Claims	

2. Citations and explanations
see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 26-34 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The following documents were cited in the International Preliminary Search Report, the numbering will be adhered to in the rest of the procedure:

- D1: US-A-5 789 555 (POLLAK ALFRED) 4 August 1998 (1998-08-04) cited in the application
- D2: WO 96 03427 A (GOODBODY ANNE ;POLLAK ALFRED (CA); RESOLUTION PHARM INC (CA)) 8 February 1996 (1996-02-08)
- D3: WO 93 17719 A (DIATECH INC) 16 September 1993 (1993-09-16)
- D4: WO 99 40947 A (ESHIMA DENNIS ;POLLAK ALFRED (CA); THORNBACK JOHN (CA); FAUCONNIER) 19 August 1999 (1999-08-19)
- D5: SMITH, C. J. (1) ET AL: 'Evaluation of a novel N3S chelation system for the preparation of Tc-99m and Re-188 labeled biomolecules.' JOURNAL OF NUCLEAR MEDICINE, (MAY, 1998) VOL. 39, NO. 5 SUPPL., PP. 215P. MEETING INFO.: 45TH ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE TORONTO, ONTARIO, CANADA JUNE 7-11, 1998 SOCIETY OF NUCLEAR MEDICINE. , XP002125500
- D6: WONG, ERNEST (1) ET AL: 'Synthesis and structural characterization of Tc-99m and Re oxo complexes with N-1N'2S-1 peptidic ligands.' JOURNAL

OF NUCLEAR MEDICINE, (1997) VOL. 38, NO. 5 SUPPL., PP. 184P.
MEETING INFO.: 44TH ANNUAL MEETING OF THE SOCIETY OF
NUCLEAR MEDICINE SAN ANTONIO, TEXAS, USA JUNE 1-5, 1997 ,
XP002125501

D7: US-A-5 659 041 (DUNN-DUFAULT ROBERT ET AL) 19 August 1997
(1997-08-19)

Novelty - Article 33(2) PCT

Document D1 discloses a composition for generating a metal labelled imaging agent comprising: (a) a solid support (b) a linking group bound to the solid support and (c) a conjugate comprising a ligand and a targeting molecule, where the ligand incorporates a metal coordinating atom that is coupled to the linking group by a bond cleavable by the metal.

Document D2 discloses radionuclide chelators encompassing the ones of the current invention, but no solid support is used.

Document D3 relates to Tc-99m labeled radiodiagnostic agents, methods and kits for making such agents, and methods for using such agents to image sites of infection and inflammation. A reagent for preparing a scintigraphic imaging agent, comprising a binding peptide that specifically binds to leukocytes, covalently linked to a technetium 99m binding moiety, is disclosed. The radiolabelled moiety may be linked to the specific binding peptide during solid phase peptide synthesis (claims 1 and 26-29).

D5 discloses dimethylglycine-serine-cysteine-glycine as chelator for Tc-99m and Re-188 (abstract). No solid support appears to be utilized.

D6 describes the use of dimethylglycine-serine-cysteine-glycine (RP261) and dimethylglycine-isoleucine-cysteine-glycine (RP349) as chelators for Tc-99m and Re to be used as radiopharmaceuticals and as inflammation imaging agents (abstract).

D7 discloses chelators of N₃S-type for Tc-99m and Re to be used in diagnostic and therapeutic applications. The targeting peptide moiety can be immobilized on a solid

support. (claims 1, 32, 33).

None of the above documents disclose a metal solid support for reversibly binding metal-ligand complexes without any linking group. The subject-matter of claims 1-44 therefore appears to be novel.

Inventive Step - Article 33(3) PCT

The problem to be solved appears to be the provision of a solid support radiopharmaceutical preparation being labelled to a high degree, that resists chemical/radiolytical/thermal degradation, that eliminates synthetic steps associated with linker and eliminates the use of noxious sulfur-protecting agents.

The solution appears to be the use of a metal solid support to which the surface binding cysteine sulphur binds reversibly.

No hints appear to be present in the prior art that would render the solution obvious. Therefore, the subject-matter of claims 1-44 appears to be inventive.

Industrial Applicability - Article 33(4) PCT

For the assessment of the present claims 24-34 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Re Item VI

Certain documents cited

The following document is presently not taken into account when assessing on novelty and inventive step, as it does not belong to the prior art (Rule 64.3 PCT). This document might, however, become relevant for the assessment of novelty in the regional (European) phase.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/CA99/00700

Certain published documents (Rule 70.10)

Document	Filing date	Priority date	Publication date
D4 (WO99/40947)	11.02.99	11.02.98	19.08.99

D4 appears however not to disclose labelled releasable conjugates bound to a metal support surface.

Re Item VIII

Certain observations on the international application

The definition of the conjugate in claim 1 as being "capable of coordinating with a complex-forming metal ion" uses a desirable property to define the subject-matter, instead of structural, technical features. A similar definition is given for the metal support in claim 2. Claims 1 and 2 do therefore not fulfill the requirements of clarity (Article 6 PCT).

Multiple dependant claims shall not serve as a basis for any other multiple dependant claim (Rule 6.4(a) PCT), which is the case for several of the claims on file. The claims should be concise in their entirety as well as individually (PCT Guidelines III-5.1).

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 2282/2603	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/CA 99/ 00700	International filing date (day/month/year) 03/08/1999	(Earliest) Priority Date (day/month/year) 17/02/1999
Applicant RESOLUTION PHARMACEUTICALS INC. et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 99/ 00700

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
See FURTHER INFORMATION SHEET PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.1

Although claim(s) 39,41-47 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 40-47 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

International Application No.

T/CA 99/00700

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K51/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 789 555 A (POLLAK ALFRED) 4 August 1998 (1998-08-04) cited in the application claims ---	
A	WO 96 03427 A (GOODBODY ANNE ; POLLAK ALFRED (CA); RESOLUTION PHARM INC (CA)) 8 February 1996 (1996-02-08) claims ---	1-53
Y	WO 93 17719 A (DIATECH INC) 16 September 1993 (1993-09-16) claims 1,26-29 ---	1-53
P, X	WO 99 40947 A (ESHIMA DENNIS ; POLLAK ALFRED (CA); THORNBACK JOHN (CA); FAUCONNIER) 19 August 1999 (1999-08-19) claims --- -/--	1-53

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 December 1999

Date of mailing of the international search report

28/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

International Application No

/CA 99/00700

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SMITH, C. J. (1) ET AL: "Evaluation of a novel N3S chelation system for the preparation of Tc-99m and Re-188 labeled biomolecules." JOURNAL OF NUCLEAR MEDICINE, (MAY, 1998) VOL. 39, NO. 5 SUPPL., PP. 215P. MEETING INFO.: 45TH ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE TORONTO, ONTARIO, CANADA JUNE 7-11, 1998 SOCIETY OF NUCLEAR MEDICINE. , XP002125500 ---	
Y	WONG, ERNEST (1) ET AL: "Synthesis and structural characterization of Tc-99m and Re oxo complexes with N-1N'2S-1 peptidic ligands." JOURNAL OF NUCLEAR MEDICINE, (1997) VOL. 38, NO. 5 SUPPL., PP. 184P. MEETING INFO.: 44TH ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE SAN ANTONIO, TEXAS, USA JUNE 1-5, 1997 , XP002125501 page 184P, paragraphs NO.,790 ---	1-53
A	US 5 659 041 A (DUNN-DUFAULT ROBERT ET AL) 19 August 1997 (1997-08-19) claims 1,32,33 -----	1-53

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

CA 99/00700

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5789555	A	04-08-1998	AU 8137694 A EP 0730472 A JP 9505061 T	06-06-1995 11-09-1996 20-05-1997
WO 9603427	A	08-02-1996	US 5662885 A AU 700772 B AU 2301195 A CA 2194551 A CN 1158133 A EP 0772628 A HU 77137 A JP 10502931 T NO 970273 A US 5976495 A US 5780006 A	02-09-1997 14-01-1999 22-02-1996 08-02-1996 27-08-1997 14-05-1997 02-03-1998 17-03-1998 12-03-1997 02-11-1999 14-07-1998
WO 9317719	A	16-09-1993	AU 683015 B CA 2131816 A EP 0630265 A JP 7504902 T US 5711931 A US 5807538 A US 5965107 A	30-10-1997 14-09-1993 28-12-1994 01-06-1995 27-01-1998 15-09-1998 12-10-1999
WO 9940947	A	19-08-1999	NONE	
US 5659041	A	19-08-1997	AT 162524 T AU 7261994 A CA 2167167 A WO 9503280 A DE 69408145 D DE 69408145 T EP 0710228 A ES 2114209 T GR 3026658 T JP 9500140 T	15-02-1998 20-02-1995 02-02-1995 02-02-1995 26-02-1998 03-09-1998 08-05-1996 16-05-1998 31-07-1998 07-01-1997